IRIS UniCatt

Di Giambenedetto, Simona
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.232
EU - Europa 8.040
AS - Asia 3.391
SA - Sud America 776
AF - Africa 79
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 11
Totale 20.543
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.109
DE - Germania 2.045
SE - Svezia 1.493
SG - Singapore 1.270
CN - Cina 1.179
IT - Italia 888
FR - Francia 887
PL - Polonia 759
BR - Brasile 714
UA - Ucraina 613
IE - Irlanda 447
ID - Indonesia 272
IN - India 254
GB - Regno Unito 250
FI - Finlandia 233
RU - Federazione Russa 157
TR - Turchia 85
CA - Canada 80
BE - Belgio 57
HK - Hong Kong 56
IR - Iran 46
AT - Austria 42
NL - Olanda 42
KR - Corea 37
JP - Giappone 28
VN - Vietnam 28
ES - Italia 22
MX - Messico 22
AR - Argentina 20
CH - Svizzera 20
CI - Costa d'Avorio 19
MA - Marocco 16
BD - Bangladesh 15
LT - Lituania 15
KZ - Kazakistan 13
PK - Pakistan 12
ZA - Sudafrica 12
UZ - Uzbekistan 11
IQ - Iraq 10
AU - Australia 9
CL - Cile 9
CM - Camerun 9
CZ - Repubblica Ceca 9
EC - Ecuador 9
PE - Perù 9
EU - Europa 8
RO - Romania 8
TW - Taiwan 8
AE - Emirati Arabi Uniti 7
AZ - Azerbaigian 6
BG - Bulgaria 6
CO - Colombia 6
GR - Grecia 6
LV - Lettonia 6
DK - Danimarca 5
IL - Israele 5
JM - Giamaica 5
NZ - Nuova Zelanda 5
PA - Panama 5
PH - Filippine 5
PY - Paraguay 5
TH - Thailandia 5
KG - Kirghizistan 4
LA - Repubblica Popolare Democratica del Laos 4
NG - Nigeria 4
NO - Norvegia 4
PT - Portogallo 4
TN - Tunisia 4
AL - Albania 3
BY - Bielorussia 3
DZ - Algeria 3
EG - Egitto 3
GE - Georgia 3
HN - Honduras 3
IM - Isola di Man 3
KE - Kenya 3
MY - Malesia 3
OM - Oman 3
BN - Brunei Darussalam 2
BO - Bolivia 2
BZ - Belize 2
CY - Cipro 2
DO - Repubblica Dominicana 2
EE - Estonia 2
HR - Croazia 2
JO - Giordania 2
LK - Sri Lanka 2
LU - Lussemburgo 2
NI - Nicaragua 2
NP - Nepal 2
RS - Serbia 2
SA - Arabia Saudita 2
TZ - Tanzania 2
VE - Venezuela 2
XK - ???statistics.table.value.countryCode.XK??? 2
YE - Yemen 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BT - Bhutan 1
Totale 20.527
Salva come PNG Salva come JPEG
Città #
Chandler 1.897
Singapore 729
Ashburn 700
Kraków 599
Dublin 440
Jacksonville 416
New York 390
San Mateo 381
Jakarta 271
Milan 256
Nanjing 227
Wilmington 217
Boston 182
Ann Arbor 181
Dearborn 164
Warsaw 153
Houston 152
Cattolica 126
Princeton 124
Lawrence 122
Nürnberg 110
Rome 109
Beijing 108
Woodbridge 105
Redwood City 103
Moscow 102
Los Angeles 99
Nanchang 95
Helsinki 89
Seattle 80
Marseille 77
Redmond 74
The Dalles 68
Izmir 66
Fairfield 58
Brussels 57
Boardman 56
Chicago 56
Lancaster 56
Hefei 55
Bremen 53
Düsseldorf 52
Shenyang 52
São Paulo 51
Mountain View 49
Frankfurt am Main 48
Hong Kong 48
Munich 46
Norwalk 45
Changsha 42
Pune 42
Kunming 41
Nuremberg 40
Hebei 37
University Park 37
Augusta 33
London 32
Guangzhou 31
Lauterbourg 31
Seoul 31
Verona 31
Ottawa 30
Toronto 30
Shanghai 28
Tianjin 28
Vienna 28
Hangzhou 27
Leawood 27
Cambridge 25
Fremont 25
Jiaxing 25
Jinan 25
Andover 24
Santa Clara 24
Washington 23
Amsterdam 21
Belo Horizonte 21
Kish 19
Portsmouth 19
Abidjan 18
Paris 18
Philadelphia 18
Rio de Janeiro 18
Falls Church 17
Roubaix 17
Trieste 17
Brooklyn 15
San Jose 14
Zhengzhou 14
Edinburgh 13
Falkenstein 12
Brasília 11
Busto Arsizio 11
Campinas 11
Changchun 11
Curitiba 11
Hanoi 11
Simi Valley 11
Tashkent 11
Almaty 10
Totale 10.960
Salva come PNG Salva come JPEG
Nome #
Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR 331
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 235
Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility 192
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 189
Liver fibrosis is associated with cognitive impairment in HIV-positive patients 179
Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk 176
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 171
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 167
Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance 162
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 149
Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia 148
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study 147
Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients 145
Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE) 145
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 144
Variability of raltegravir plasma levels in the clinical setting 141
Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure 141
Assessment of neurological manifestations in hospitalized patients with COVID-19 137
Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010. 135
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 134
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy. 133
Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. 132
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 132
Prospective evaluation of epidemiological, clinical, and microbiological features of pandemic influenza A (H1N1) virus infection in Italy 126
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 123
Validation of an UPLC-MS/MS Method for Quantitative Analysis of Raltegravir in Human Plasma Samples 121
Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction 120
Clinical presentation, microbiological features and correlates of disease severity of 2009 pandemic influenza A (H1N1) infection 119
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 119
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy 119
Verbal list learning and memory profiles in HIV-infected adults, Alzheimer's disease, and Parkinson's disease: An evaluation of the "cortical hypothesis" of NeuroAIDS 119
Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure. 118
The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy 118
Predictors of successful genotype-guided antiretroviral therapy in treatment-experienced individuals over calendar year: a cohort study 117
Cardiovascular risk factors and carotid intima-media thickness are associated with low cognitive performance in HIV-infected patients 116
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 116
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection 114
Cognitive reserve and neuropsychological functioning in older HIV-infected people 114
Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: two years experience in routine clinical practice 113
Effect of aging and human immunodeficiency virus infection on cognitive abilities 112
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 112
Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study 111
Virological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1 110
Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction? 108
Macrophage chemoattractant protein-1 levels in cerebrospinal fluid correlate with containment of JC virus and prognosis of acquired immunodeficiency syndrome--associated progressive multifocal leukoencephalopathy. 108
HIV-infected patients show impaired cellular immune response to influenza vaccination, compared to healthy subjects 108
Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients. 107
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen 107
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 107
Comparison of cognitive performance in HIV or HCV mono-infected and HIV-HCV co-infected patients 106
Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1 106
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 105
Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis 104
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 103
HIV-infected patients show impaired cellular immune response to influenza vaccination compared to healthy subjects 102
Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study 102
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients 102
Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study. 101
Dolutegravir Plus Lamivudine as First-Line Regimen in a Multicenter Cohort of HIV-1-Infected Patients: Preliminary Data from Clinical Practice 101
Psychological distress during the initial stage of the COVID-19 pandemic in an italian population living with HIV: An online survey 100
Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy 99
Detection of HLA-B*57:01 by real-time PCR: implementation into routine clinical practice and additional validation data 99
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 99
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial 99
Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. 98
Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure 98
HIV-Related Internalized Stigma and Patient Health Engagement Model in an Italian Cohort of People Living With HIV 98
Mortality in patients with early- or late-onset candidaemia 97
Genotypic resistance profile and clinical progression of treatment-experienced HIV type 1-infected patients with virological failure. 96
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA 96
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 95
Mortality in patients, with early-or late-onset candidaemia 95
Prevalence of transmitted HIV-1 drug resistance in HIV-1 infected patients in Italy: evolution over 12 years and predictors 94
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 94
Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients 92
Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe 92
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 92
Shall we dance? Extending tango's results to clinical practice 92
Fatal inflammatory AIDS-associated PML with high CD4 counts on HAART: a new clinical entity? 91
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 90
Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients 90
Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 89
Lipid-lowering effect of tenofovir in HIV-infected patients 89
Long term follow-up of Nevirapine-treated patients in a single centre cohort 88
Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients 88
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis 88
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 88
Difference in the neurocognitive functions of WLWH and MLWH in an Italian cohort of people living with HIV 88
The threshold bootstrap clustering: a new approach to find families or transmission clusters within molecular quasispecies 86
Declining tuberculosis and drug resistance rate among HIV-positive patients at an Italian teaching hospital in the era of highly active antiretroviral therapy 86
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: A multicenter observational study 86
A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients 86
Evolution and predictors of HIV type 1 drug resistance in patients failing combination antiretroviral therapy in Italy 85
Prevalence, incidence and predictors of anal high-risk HPV infections and cytological abnormalities in HIV-infected individuals 85
Exploratory analysis for the evaluation of estimated glomerular filtration rate, cholesterol and triglycerides after switching from tenofovir/emtricitabine plus atazanavir/ritonavir (ATV/r) to abacavir/lamivudine plus ATV/r in patients with preserved renal function 85
Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice 85
Coccidioidomycosis of cervical lymph nodes in an HIV-infected patient with immunologic reconstitution on potent HAART: a rare observation in a nonendemic area 83
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 83
Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine 82
A novel methodology for large-scale phylogeny partition 82
Totale 11.507
Salva come PNG Salva come JPEG
Categoria #
all - tutte 98.823
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 98.823
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020156 0 0 0 0 0 0 0 0 0 0 0 156
2020/20211.462 112 155 33 145 183 86 150 24 210 77 247 40
2021/20222.129 176 125 41 176 76 64 98 377 79 156 300 461
2022/20234.801 652 732 365 689 376 592 143 397 589 58 150 58
2023/20242.546 96 666 52 314 97 509 120 49 59 72 287 225
2024/20254.048 78 109 460 152 459 183 216 273 701 414 938 65
Totale 20.878